Coya Therapeutics to progress trial of ALS treatment upon FDA approval

The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application from Coya Therapeutics for COYA 302, enabling the company to begin a phase 2 clinical trial in patients with amyotrophic lateral sclerosis (ALS). The study will assess the safety and efficacy of COYA 302, a biologic therapy designed to regulate […]